跳到正文
原文
MedPage Today·· 10 天前精选AI 评分75

常用抗生素多西环素与妊娠早期流产风险增加相关

Common Antibiotic Tied to Pregnancy Loss Risk

AI 导读

一项队列研究显示,多西环素用于治疗呼吸道感染或痤疮的孕妇流产风险较高,提示临床需权衡用药益处。

推荐理由

研究发现常用抗生素多西环素可能增加妊娠早期流产风险,提示临床需权衡用药益处。

正文

— Pregnant women may want to weigh benefits of doxycycline against risks, experts said

by Rachael Robertson, Enterprise & Investigative Writer, MedPage Today

November 9, 2026 • 3 min read

  • Women exposed to doxycycline had higher risk for pregnancy loss than those prescribed other antibiotics for respiratory tract infection or acne.
  • This trend persisted among both commercially and publicly insured women.
  • While doxycycline is generally not recommended in pregnancy, many women of childbearing age are exposed, some of whom may not know they're pregnant.

Women exposed to doxycycline in early pregnancy had an increased risk of pregnancy loss compared to other antibiotics, a cohort study showed.

Doxycycline use for respiratory tract infection was linked with increased pregnancy loss risk compared with amoxicillin use among pregnant women with both public and private insurance (Medicaid adjusted risk ratio [aRR] 1.40, 95% CI 1.28-1.53 and MarketScan aRR 1.54, 95% CI 1.41-1.68]), reported Almut Winterstein, PharmD, PhD, of the University of Florida in Gainesville, and colleagues.

Compared with macrolide antibiotics, doxycycline was still associated with increased risk of pregnancy loss for this indication (MarketScan aRR 1.39, 95% CI 1.28- 1.51, and Medicaid aRR 1.36, 95% CI 1.25-1.48), they wrote in Annals of Internal Medicine.

Among patients with acne, doxycycline had a significantly higher risk of pregnancy loss than topical clindamycin among those privately insured (aRR 1.49, 95% CI 1.26-1.76) but not publicly insured (aRR 1.03, 95% CI 0.80-1.33), the researchers found.

"Our findings suggest that clinicians, together with their patients, might want to weigh the benefits against the potential risk for pregnancy loss when considering doxycycline for reproductive-aged women," they wrote.

Janna Morrison, PhD, of Adelaide University in Australia, who was not involved in the study, said in comments posted to the Science Media Centre website that the results are important because they "provide the evidence required by clinicians to decide which antibiotic to prescribe to women of reproductive age or in early pregnancy."

Morrison cautioned that the study was limited because it didn't examine potential effects on the fetus, but still said the findings "may help doctors make more informed decisions about which antibiotics to prescribe to pregnant women who require treatment for conditions such as respiratory infections or acne."

Doxycycline is generally not recommended in pregnancy due to its calcium-chelating properties, which may result in discolored teeth and potential bone problems in offspring, Winterstein noted. However, it's still fairly commonly prescribed to women of childbearing age, which may include women who do not yet know they're pregnant.

For their retrospective, active-comparator study, Winterstein and colleagues analyzed claims data from Merative MarketScan (2005–2021) for commercially insured patients, and Medicaid (1999–2019) for publicly insured ones. They looked at patients receiving doxycycline or comparator antibiotics between conception and the end of the first trimester (approximately 76 days).

Doxycycline-exposed pregnancies were matched to similar ones exposed to other antibiotics. Comparators could not be exposed to doxycycline within 30 days before conception but exposure to other antibiotics during follow-up was allowed.

Pregnant women ages 12 to 55 who had continuous enrollment 90 days before estimated conception to 30 days after the end of pregnancy were included. Pregnancies with multiple gestations, exposure to teratogenic drugs, known chromosomal anomalies, and congenital anomalies identified before cohort entry date were excluded, as were patients with cancer.

The primary outcome was pregnancy loss defined as miscarriage or stillbirth at ≥20 weeks gestation.

There were 218,234 participants in all. Most were prescribed doxycycline for respiratory tract infections (110,254 in MarketScan and 107,980 in Medicaid) while the rest were prescribed it for acne (4,719 in MarketScan, 1,917 in Medicaid). Medicaid patients skewed younger than MarketScan patients for both indications.

The authors noted several limitations, including the risk of residual confounding, the possibility of misclassification, and that congenital malformations were not evaluated.

Winterstein said the team is working on another study analyzing the outcomes in live-born infants.

来源:MedPage Today · medpagetoday.com